Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 14/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 4/20 | 0.43 |
| ▸ | PKLR | P30613 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16370316 | 0.90 | PDE5A (0.57) | PDE5APKMPKLR | |
| SCHEMBL19480648 | 0.88 | PDE5A (0.56) | PDE5ACYP1A2CYP2C19PKMPKLR | |
| SCHEMBL14754722 | 0.84 | PDE5A (0.52) | PDE5ACYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL20140296 | 0.83 | PDE5A (0.45) | PDE5ACYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL14746488 | 0.82 | PDE5A (0.52) | PDE5ACYP1A2CYP2C19PKMPKLR | |
| SCHEMBL19228853 | 0.81 | PDE5A (0.41) | PDE5A | |
| SCHEMBL14746117 | 0.81 | PDE5A (0.56) | PDE5ACYP1A2CYP2C19PKMPKLR | |
| SCHEMBL14754825 | 0.80 | PDE5A (0.49) | PDE5ACYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL19228854 | 0.80 | PDE5A (0.56) | PDE5APKMPKLRKMT2A | |
| SCHEMBL174461 | 0.78 | PDE5A (0.52) | PDE5AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3007556-A2 | CELL STABILIZATION | Biomatrica, INC. (US) | 2016-04-20 | — | — | EP | claimed |
| WO-2015002729-A2 | CELL STABILIZATION | BIOMATRICA, INC. (US) | 2015-01-08 | — | — | WO | claimed |
| EP-2751106-B1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER IP GMBH (DE) | 2017-10-18 | — | — | EP | disclosed |
| EP-2751106-B1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER IP GMBH (DE) | 2017-10-18 | — | — | EP | disclosed |
| US-20170240566-A1 | AMINO-SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-24 | — | — | US | disclosed |
| US-20170240566-A1 | AMINO-SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-24 | — | — | US | disclosed |
| US-20170233413-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-17 | — | — | US | disclosed |
| US-20170233413-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-17 | — | — | US | disclosed |
| US-9505786-B2 | Substituted annulated triazines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-29 | — | — | US | disclosed |
| US-9505786-B2 | Substituted annulated triazines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-29 | — | — | US | disclosed |
| EP-3007556-A2 | CELL STABILIZATION | Biomatrica, INC. (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-04 | — | — | US | disclosed |
| EP-2802592-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8859569-B2 | Substituted annellated pyrimidines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859569-B2 | Substituted annellated pyrimidines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-14 | — | — | US | disclosed |
| EP-2751106-A1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013104703-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013104703-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013029116-A1 | METHOD FOR PREDICTING TREATMENT RESPONSIVENESS | MONASH UNIVERSITY (AU) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013030288-A1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240566-A1 | AMINO-SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | TYMP, TYMS, DPYD | PDE5A 1769/4885CYP1A2 1187/4885CYP2C19 573/4885 |
| US-20170233413-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | TYMP, DPYD, TYMS | PDE5A 1936/4885CYP1A2 742/4885CYP2C19 337/4885 |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | TYMP, DPYD, TYMS | PDE5A 1705/4885CYP1A2 363/4885CYP2C19 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.